HCC in the second-line setting. meetinglibrary.asco.org/record/173190/…
Durvalumab +/- tremelimumab in second-line metastatic head and neck cancer not better than SOC chemo (including methotrexate!). Do not use durvalumab. meetinglibrary.asco.org/record/175441/…